ADC Therapeutics SA (ADCT) Misses Q4 EPS by 51c

ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.97), $0.51 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $16.79 million versus the consensus estimate of $15.32 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform